Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Thai hospital tycoon who promised Pfizer vaccine says deal now unlikely

08/04/2021 | 03:10am EDT
FILE PHOTO: Chairman of Thonburi Healthcare Group, Boon Vanasin speaks during interview with Reuters in Bangkok

BANGKOK (Reuters) - The chair of Thailand's Thonburi Healthcare Group (THG) said on Wednesday that a deal to import 20 million doses of the Pfizer-BioNTech COVID-19 vaccine was unlikely to happen, despite his earlier claims that a deal was close.

Thailand is battling its biggest COVID-19 outbreak yet, and has been racing to secure vaccines. Last month, THG Chairman Boon Vanasin said talks to clinch a deal with BioNTech was nearing conclusion, but both Pfizer and BioNTench said they were not in talks with THG.

"Our problem is that we are unable to import it because it has to come through a government agency," Boon said during a televised interview with the MCOT television station on Wednesday. "I think we won't be able to do it," he added.

Boon did not say with which importer his group had been working. THG shares fell 8.13% on Wednesday along a benchmark decline of 0.35%.

Last month, BioNTech denied it was in talks with THG while a Pfizer spokesman said the company was only in discussions with Thailand's health ministry and disease control department.

Boon had previously said he was working to secure the vaccines indirectly, via an unnamed government agency.

Thailand has since late April been faced with a surge in COVID-19 infections, driven by the highly contagious Delta variant of the coronavirus.

The Southeast Asian country's main vaccine rollout began in June and has depended mainly on Sinovac and locally manufactured AstraZeneca vaccines.

Just over 6% of Thailand's 66 million population been fully vaccinated so far. Delays in the government inoculation programme have been compounded than lower than expected local manufacturing capacity of the AstraZeneca vaccine.

The government has struck a deal for 20 million doses of the Pfizer vaccine, due to arrive later this year, and says it has plans to purchase an additional 10 million doses.

($1 = 33.0700 baht)

(Reporting by Panu Wongcha-um and Chayut Setboonsarng; Editing by James Pearson)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 6.04% 8550 Delayed Quote.10.09%
SINOVAC BIOTECH LTD. -0.31% 6.47 Delayed Quote.0.00%
THONBURI HEALTHCARE GROUP PUBLIC COMPANY LIMITED 0.78% 32.25 End-of-day quote.25.24%
All news about ASTRAZENECA PLC
04:44pTHE LATEST : EU official: US isn't being loyal or transparent
AQ
04:35pASTRAZENECA : White House plan to allow foreign visitors silent on easing Canada..
AQ
11:12aEuropean ADRs Move Sharply Lower in Monday Trading
MT
11:07aDAIICHI SANKYO : Enhertu reduced the risk of disease progression or death by 72%..
AQ
11:07aASTRAZENECA : Imfinzi plus chemotherapy tripled patient survival at three years ..
AQ
11:07aDAIICHI SANKYO : Enhertu demonstrated robust and durable tumour response of 54.9..
AQ
10:25aASTRAZENECA : SVB Leerink Adjusts AstraZeneca's PT to $71 from $69, Keeps Outper..
MT
09:53aGRITSTONE BIO : Oncology Doses First Volunteer in Phase 1 Trial of COVID-19 Vacc..
MT
07:58aASTRAZENECA : Credit Suisse remains its Buy rating
MD
07:56aASTRAZENECA : Buy rating from JP Morgan
MD
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 247 M - -
Net income 2021 5 006 M - -
Net Debt 2021 24 250 M - -
P/E ratio 2021 23,9x
Yield 2021 3,29%
Capitalization 133 B 181 B -
EV / Sales 2021 4,45x
EV / Sales 2022 3,57x
Nbr of Employees 76 100
Free-Float 96,3%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 85,59 $
Average target price 136,00 $
Spread / Average Target 58,9%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC10.09%171 794
JOHNSON & JOHNSON4.09%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.19.23%246 078
NOVO NORDISK A/S50.80%232 556
ELI LILLY AND COMPANY37.19%208 604